SmartPeople: Dr Vlado Perkovic
Dr Vlado Perkovictalks to PharmaTimes about his hopes for Novo Nordisk’s FLOW trial, and the need to tackle the growing burden of chronic kidney disease (CKD) in the type II diabetes population.
3rd June 2019
Web Exclusives
Are PCSK9 inhibitors about to take off?
Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.
27th May 2019
Outward looking UK scientists among global leaders in the fight against melanoma
Elsevier's Maria de Kleijn-Lloyd looks at UK researchers’ contribution to the fight against melanoma
21st May 2019
Will healthcare be a casualty of the EU’s populist surge?
With EU parliament elections fast approaching, Nick Hoile, director of Government Affairs at Publicis Resolute, considers the potential impact of a more Eurosceptic climate on health.
13th May 2019
Big pharma - come back to mental health and invest in Europe
As Mental Health Awareness Week 2019 begins (13/5/19), King’s College London Professor of Psychiatry Allan Young offers his thoughts on how a new European pharmacovigilance consortium could pave the way for new mental health drugs for UK patients.
13th May 2019
NHS prescribing is back in the spotlight – where does tech fit?
Dr Simon Hendricks, clinical strategy lead at FDB (First Databank), is excited by the recent attention from Whitehall to improving NHS prescribing. He asks what progress is already being made, what needs to happen next, and where technology can play a role.
10th May 2019
SmartPeople: Jenna McDonnell
PharmaTimes talks to Jenna McDonnell, Program Manager, Project Delivery & Operational Leader for TrialConsent, at clinical research technology group CRF Bracket
8th May 2019
Can pharma survive as data-driven therapy takes centre stage?
The rise of digital therapeutics and the shift of the health market towards payment for outcomes could be seen as a significant double threat to pharma. However, cross-industry collaboration could turn these threats into opportunities, says S3 Connected Health's Jim O’Donoghue.
8th May 2019
Embedding ethics in pharma’s DNA
Compliance training should focus on promoting trust and integrity, rather than on fear of the consequences of non-compliance. Louise Vamvoukaki offers an insight into how AstraZeneca is working to ensure that its globally dispersed workforce are all living and breathing the same values and ethics.
25th April 2019
Addressing the diversity challenge in clinical trials
Solving the challenge of increasing minority participation in clinical trials requires a long-term commitment and investment from the research community.
25th April 2019
Nothing less than a bleed-free life
To mark World Haemophilia Day, Laurence Woollard talks to PharmaTimes about engaging today’s generation of young people living with the condition to advocate for nothing less than a bleed-free life
17th April 2019
Lonely at the top?
Ex England cricketer Jeremy Snape says pharma leaders looking to inspire their teams during volatile times should see what lessons they can learn from other industries faced with similar challenges
15th April 2019
The search for a cure for Alzheimer’s is far from over
Patent-mapping research suggests that innovation-led newcomers may already be on to something new
28th March 2019
AI and pharma sales
Alex Dale looks at where we are with AI and how it might help pharma sales
28th March 2019
Sanofi's Hugo Fry talks Brexit
Sanofi UK's managing director Hugo Fry shares his thoughts on Brexit
26th March 2019
